



---

**FOR IMMEDIATE RELEASE**

### **Lee's Pharmaceutical Appoint Dr. Lit-Fui Lau to its Senior Management Team**

Hong Kong, China (October 4, 2012) – Lee's Pharmaceutical Holdings Limited ("Lee's") today announced that Dr. Lit-Fui Lau has joined the Company as Senior Director of Development of CVie Therapeutics Company Limited ("CVie") and General Manager of Shanghai of Zhaoke Pharmaceutical (Hefei) Company Limited ("Zhaoke"), the subsidiaries of Lee's Pharmaceutical Holdings Ltd.

For over 14 years, Dr. Lau had participated in the preclinical development of a number of novel compounds in multiple therapeutic areas and he has had responsibility and tract record in moving compounds into the clinical development stage in the CNS area.

"Having Lit-Fui on board of the executive team of CVie Therapeutics at this critical juncture will undoubtedly facilitate the development of the Company's two important assets", said Dr. Benjamin Li, the Chief Executive Officer of Lee's Pharmaceutical Holdings Ltd. "He brings with him a wealth of knowledge in drug development and extensive experience in the pharmaceutical industry. As Shanghai is becoming the hubs of drug development in China, his leadership as the head of the Group's operation in Shanghai will help to better position the Company in the industry and accelerate the growth of business in these important areas. This is one of many steps that the Group is taking to strengthen its management team and to improve its operation efficiency".

Dr. Lau most recently served as Associate Director for GlaxoSmithKline R&D China, where he played a key role in establishing a brand new business unit on traditional Chinese medicine. As the Head of the Neurodegeneration DPU (Discovery Performance Unit) at GSK R&D China, Dr. Lau was responsible for setting its research directions, building its portfolio, establishing its infrastructure, and advancing a compound into the clinic for the treatment of Alzheimer's disease. Previously, he served Pfizer as the head of a biology laboratory and leader of multiple drug discovery programs. Dr. Lau's experience covers a wide range of areas from drug target identification and validation, high throughput screening, lead optimization, clinical candidate selection, preclinical development, early clinical development to in-licensing of drugs and technologies. Dr. Lau received his B.Sc. and M.Phil. from the Chinese University of Hong Kong and Ph.D. from the University of Connecticut Health Center. He conducted his postdoctoral fellowship in the Department of Neuroscience at the Johns Hopkins University School of Medicine.



### **About Lee's Pharmaceutical**

Lee's Pharmaceutical Holdings Limited ("Lee's") is a research-based Hong Kong biopharmaceutical company with over 18 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with 20 international companies and currently has 13 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. For further information about Lee's Pharmaceutical: Website: [www.leespharm.com](http://www.leespharm.com)

### **About CVie**

CVie is a joint venture between Lee's Pharmaceutical Holdings Ltd. and a reputable US venture capital and is a stand along drug development company specialized in cardiovascular diseases. CVie owns two phase II assets that target cardiovascular disease with significant unmet medical need. In its first day of operation, CVie has successfully filed to the SFDA the application for a global Phase IIb clinical study (Protocol No. CVT-CT-1207-001) in China for one of its portfolio products Rostafuroxin. The study aims to using pharmacogenomic approach to evaluate the antihypertensive effect of different doses of Rostafuroxin in comparison with Losartan®, assessed by office and ambulatory blood pressure monitoring in a hypertensive population. It is expected to initiate the clinical trial respectively in Italy at Q4 2012 and in China at Q3 2013.

### **About Zhaoke**

Zhaoke is a wholly owned subsidiary of Lee's Pharmaceutical Holdings Ltd. The business activities of the Group in China are primarily carried out through Zhaoke, with its manufacturing site located at Hefei, Anhui Province in the PRC. Zhaoke is an integrated research-driven and market-oriented pharmaceutical company engaged in the development, manufacture and sales of quality biopharmaceutical products that focus on several disease areas with significant unmet medical need. Currently, it has three operation centers located in Beijing, Shanghai and Guangzhou respectively.



**Safe Harbor Statement**

*The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Main Board of the Stock Exchange of Hong Kong Limited.*

*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*